Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.30B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.75M
Average 1.35M
ELVN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Enliven Therapeutics, Inc.NASDAQ: ELVN
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $27.7M (cash outflow) rose 37.5% year over year, ahead of the +16.7% change in trailing-twelve-month net income. Sequentially, it fell 14.7% from the prior quarter. Over 3 fiscal years it compounded at +40.2% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$111.04M (+7.1%) for the fiscal year ending Dec 2026, a slowdown from the +16.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$27.7M-14.7% QoQ
- Last fiscal yearDec 2025
- -$103.69M+16.5% YoY
- LTMSep 2026
- -$113.48M+16.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +37.5% | +13.1% | -24.4 pp |
| 1 year | +16.5% | +7.1% | -9.4 pp |
| 3-year CAGR | +40.2% | +11.7% | -28.4 pp |
| 5-year CAGR | -9.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (103.69M) USD
- Year-over-year change
- -16.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (103.69M) | -16.5% |
| FY2024 | 2024-12-31 | (89.02M) | -24.4% |
| FY2023 | 2023-12-31 | (71.58M) | -90.1% |
| FY2022 | 2022-12-31 | (37.66M) | -52.2% |
| FY2021 | 2021-12-31 | (24.74M) | — |
Net Income vs competitors
How ELVN compares with its peers on the latest reported figures
- ELVN's LTM Sep 2026 net income of $113.48M is the 10th largest of the 11 companies compared; the peer median is $140.23M.
- Its year-over-year change of +16.7% is the 7th highest of 11, against a peer median of +29.8%.
- Over three fiscal years its annual growth of +40.2% compares with a peer median of +29.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.77B | +117.8% | +65.7% | — | |
| LTM Jun 2026 | $1.61B | +85.1% | +55.7% | 27.7% | |
| LTM Jul 2026 | $860.62M | +42.9% | +62.5% | 35.3% | |
| LTM Jun 2026 | $286.04M | -8.2% | -1.6% | 2763.6% | |
| LTM Mar 2026 | $243.25M | -26.6% | +24.1% | 112.0% | |
| LTM Mar 2026 | $221.04M | +23.7% | — | — | |
| LTM Mar 2026 | $145.24M | +14.0% | +65.2% | — | |
| LTM Mar 2026 | $135.21M | +1.8% | +13.3% | — | |
| LTM Mar 2026 | $131.11M | +36.0% | +29.4% | — | |
| LTM Sep 2026 | $113.48M | +16.7% | +40.2% | — | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| Peer median (excluding ELVN) | $140.23M | +29.8% | +29.4% | 66.1% | |
Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.74M) | (37.66M) | (71.58M) | (89.02M) | (103.69M) |
| Depreciation & Amortization | 115K | 215K | 297K | 317K | 263K |
| Deferred Income Tax | (3.81M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.92M | 3.19M | 12.91M | 20.17M | 34.02M |
| Change in Working Capital | 3.57M | 438K | 1.4M | (4.54M) | (1.12M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.73M | 411K | (2.25M) | 810K | 817K |
| Other Working Capital | 1.83M | 27K | 3.65M | (5.35M) | (1.94M) |
| Other Non-Cash Items | 3.81M | 1.74M | (4.3M) | (118K) | 232K |
| Operating Cash Flow | (19.13M) | (32.08M) | (61.27M) | (73.19M) | (70.3M) |
| Capital Expenditures | (191K) | (612K) | (149K) | (44K) | (158K) |
| Acquisitions (Net) | 0 | 35M | 0 | 0 | 0 |
| Purchases of Investments | (47.56M) | (35M) | (268.26M) | (350.74M) | (446.79M) |
| Sales of Investments | 45.94M | 41.88M | 120M | 313.91M | 272.9M |
| Other Investing Activities | 1.62M | (41.88M) | 0 | 873K | 213K |
| Investing Cash Flow | (191K) | (612K) | (148.41M) | (36M) | (173.84M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (1.02M) | (1.23M) | 161.2M | 39.19M | 218.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (566K) | 73.09M | 93.98M | 0 |
| Financing Cash Flow | (1.02M) | (1.8M) | 234.29M | 133.17M | 218.87M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (20.34M) | (34.49M) | 24.61M | 23.98M | (25.28M) |
| Free Cash Flow | (19.33M) | (32.69M) | (61.42M) | (73.24M) | (70.46M) |
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$44.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.